Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: A double-blind, randomised controlled trial

dc.date.accessioned2022-01-04T20:31:44Z
dc.date.accessioned2022-10-25T18:48:00Z
dc.date.available2022-01-04T20:31:44Z
dc.date.available2022-10-25T18:48:00Z
dc.date.created2022-01-04T20:31:44Z
dc.date.issued2014
dc.identifierhttps://hdl.handle.net/20.500.12866/10590
dc.identifierLancet Infectious Diseases
dc.identifierhttps://doi.org/10.1016/S1473-3099(14)70779-0
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4785081
dc.description.abstractNeurocysticercosis causes a substantial burden of seizure disorders worldwide. Treatment with either praziquantel or albendazole has suboptimum efficacy. We aimed to establish whether combination of these drugs would increase cysticidal efficacy and whether complete cyst resolution results in fewer seizures. We added an increased dose albendazole group to establish a potential effect of increased albendazole concentrations
dc.languageeng
dc.publisherElsevier
dc.relationurn:issn:1474-4457
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectHumans
dc.subjectTreatment Outcome
dc.subjectDouble-Blind Method
dc.subjectNeurocysticercosis
dc.subjectAlbendazole
dc.subjectAnthelmintics
dc.subjectDrug-Related Side Effects and Adverse Reactions
dc.subjectPlacebos
dc.subjectPraziquantel
dc.titleEfficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: A double-blind, randomised controlled trial
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución